NYLI MacKay Convertible Class C MCCVX

Medalist Rating as of | See New York Life Investment Hub
  • NAV / 1-Day Return 18.83  /  +0.16 %
  • Total Assets 1.6 Bil
  • Adj. Expense Ratio
    1.940%
  • Expense Ratio 1.940%
  • Distribution Fee Level Above Average
  • Share Class Type Level Load
  • Category Convertibles
  • Investment Style Large Blend
  • Min. Initial Investment 1,000
  • Status Open
  • TTM Yield 3.05%
  • Turnover 33%

USD | NAV as of Sep 26, 2024 | 1-Day Return as of Sep 26, 2024, 10:29 PM GMT+0

Morningstar’s Analysis MCCVX

Will MCCVX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Still a solid choice.

Analyst Chiayi Tsui

Chiayi Tsui

Analyst

Summary

MainStay MacKay Convertible Bond’s selective mindset and steadfast investing style allow it to weather rough patches without major bruises, and a sensible, valuation-driven approach results in resilient performance.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings MCCVX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

MainStay US Government Liquidity I

4.75 73.9 Mil
Cash and Equivalents

TransMedics Group Inc. 1.5%

2.32 36.0 Mil
Corporate

Lantheus Holdings Inc 2.625%

2.31 35.9 Mil
Corporate

Microchip Technology Incorporated 0.125%

2.24 34.8 Mil
Corporate

Tetra Tech Inc 2.25%

2.08 32.3 Mil
Corporate

Biomarin Pharmaceutical Inc. 1.25%

1.82 28.3 Mil
Corporate

Merit Medical Systems Inc. 3%

1.77 27.5 Mil
Corporate

Southwest Airlines Co. 1.25%

1.76 27.4 Mil
Corporate

Post Holdings Inc. 2.5%

1.75 27.2 Mil
Corporate

Ford Motor Company 0%

1.74 27.1 Mil
Corporate

Sponsor Center